Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy

Open access
Bönhof, Gidon J, Herder, Christian, Strom, Alexander, Papanas, Nikolaos, Roden, Michael, Ziegler, Dan · 2019 · Endocrine Reviews

Abstract

Diabetic neuropathy, with its major clinical sequels, notably neuropathic pain, foot ulcers, and autonomic dysfunction, is associated with substantial morbidity, increased risk of mortality, and reduced quality of life.Despite its major clinical impact, diabetic neuropathy remains underdiagnosed and undertreated.Moreover, the evidence supporting a benefit for causal treatment is weak at least in patients with type 2 diabetes, and current pharmacotherapy is largely limited to symptomatic treatment options.Thus, a better understanding of the underlying pathophysiology is mandatory for translation into new diagnostic and treatment approaches.Improved knowledge about pathogenic pathways implicated in the development of diabetic neuropathy could lead to novel diagnostic techniques that have the potential of improving the early detection of neuropathy in diabetes and prediabetes to eventually embark on new treatment strategies.In this review, we first provide an overview on the current clinical aspects and illustrate the pathogenetic concepts of (pre)diabetic neuropathy.We then describe the biomarkers emerging from these concepts and novel diagnostic tools and appraise their utility in the early detection and prediction of predominantly distal sensorimotor polyneuropathy.Finally, we discuss the evidence for and limitations of the current and novel therapy options with particular emphasis on lifestyle modification and pathogenesis-derived treatment approaches.Altogether, recent years have brought forth a multitude of emerging biomarkers reflecting different pathogenic pathways such as oxidative stress and inflammation and diagnostic tools for an early detection and prediction of (pre)diabetic neuropathy.Ultimately, these insights should culminate in improving our therapeutic armamentarium against this common and debilitating or even life-threatening condition.(Endocrine Reviews 40: 153 -192, 2019) T he st century saw the further increase in the prevalence of diabetes and prediabetes (-).Diabetes leads to a serious increase in morbidity and mortality due to cardiovascular disease (CVD) (-) but also due to its microvascular complications (, ).Of note, diabetic foot complications are frequent in diabetes, difficult to heal, with a tendency to recur, sometimes presenting as emergencies, and generally they carry a sinister prognosis (-).In this context, prediabetes is receiving more attention, because it is now appreciated as a stage of already incipient vascular damage rather than just a condition of borderline increased glucose values ().Both macrovascular and microvascular disease may have their beginning in prediabetes and may adversely affect morbidity already at this stage ().

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2018-00107

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 221

Metadata

Authors
Bönhof, G. J., Herder, C., Strom, A., Papanas, N., Roden, M., & Ziegler, D.
Venue
Endocrine Reviews
Published
2018-09-25
Volume
40
Issue
1
Pages
153-192
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2893710862
Cited by
221
References
26
FWCI
12.62
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. https://app.cochat.ai/papers/10.1210/er.2018-00107
The paper
Bönhof, G. J., Herder, C., Strom, A., Papanas, N., Roden, M., & Ziegler, D. (2019). Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocrine Reviews. https://doi.org/10.1210/er.2018-00107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.